Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens

Summary. The growth of marrow fibroblasts from patients with myeloproliferative disorders (MPD) was investigated using platelet derived growth factor (PDGF) and human serum as mitogens in the presence of human plasma derived serum. The proliferation of fibroblasts in MPD patients was increased compared to normal individuals, especially in patients with chronic myelocytic leukaemia and essential thrombocythaemia. This increment of proliferation might be due to higher sensitivity of the fibroblasts to plasma derived serum than to PDGF, because the ratio of proliferation with PDGF to that without PDGF, when compared between patients and normals, remained unchanged. These results suggest that MPD fibroblasts are more sensitive to some factor(s) in plasma, and this fact could partially explain the pathogenesis of myelofibrosis in MPD patients.

[1]  R. Ross,et al.  The biology of platelet-derived growth factor , 1986, Cell.

[2]  P. Bernabei,et al.  Platelet‐derived growth factor(s) mitogenic activity in patients with myeloproliferative disease , 1986, British journal of haematology.

[3]  S. Arimori,et al.  Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia , 1985, British journal of haematology.

[4]  T. Deuel,et al.  Human platelet-derived growth factor. Purification and resolution into two active protein fractions. , 1981, The Journal of biological chemistry.

[5]  A. Yen,et al.  Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. , 1981, Blood.

[6]  C. Stiles,et al.  Dual control of cell growth by somatomedins and platelet-derived growth factor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Ross,et al.  Physiological quiescence in plasma‐derived serum: Influence of platelet‐derived growth factor on cell growth in culture , 1978, Journal of cellular physiology.

[8]  加藤 修 Platelet derived growth factor (PDGF) is decreased in patients with myeloproliferative disorders , 1988 .

[9]  T. Deuel,et al.  Platelet-derived growth factor: structure, function, and roles in normal and transformed cells. , 1985, Current topics in cellular regulation.

[10]  R. Gay,et al.  Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. , 1982, Blood.